[HTML][HTML] Allogeneic stem cell transplantation in myelofibrosis
Myeloproliferative neoplasm (MPN) is a category in the World Health Organization
classification of myeloid tumors. BCR-ABL1–negative MPN is a subcategory that includes …
classification of myeloid tumors. BCR-ABL1–negative MPN is a subcategory that includes …
Allogeneic stem cell transplantation for myelofibrosis in 2012
DP McLornan, AJ Mead, G Jackson… - British journal of …, 2012 - Wiley Online Library
Myelofibrosis (MF) is a heterogeneous disease for which long‐term, effective medical
therapeutic options are currently limited. The role of allogeneic haematopoietic stem cell …
therapeutic options are currently limited. The role of allogeneic haematopoietic stem cell …
Allogeneic stem-cell transplantation for myelofibrosis
N Lavi, JM Rowe, T Zuckerman - Current Opinion in Hematology, 2017 - journals.lww.com
HSCT remains a highly relevant treatment option for myelofibrosis in the era of JAK
inhibitors. Recent advances may contribute to a refined definition of HSCT eligibility and …
inhibitors. Recent advances may contribute to a refined definition of HSCT eligibility and …
Myelofibrosis: to transplant or not to transplant?
R Devlin, V Gupta - Hematology 2014, the American Society of …, 2016 - ashpublications.org
Hematopoietic cell transplantation (HCT) is the only curative therapeutic modality for
myelofibrosis (MF) at present. The optimal timing of HCT is not known in the presence of …
myelofibrosis (MF) at present. The optimal timing of HCT is not known in the presence of …
Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors
V Gupta, P Hari, R Hoffman - … Journal of the American Society of …, 2012 - ashpublications.org
The discovery of JAK2617F mutation paved the way for the development of small molecule
inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of …
inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of …
[HTML][HTML] Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis—a systematic review and meta-analysis
Allogeneic hematopoietic cell transplant (allo-HCT) remains the only potentially curative
therapeutic modality for patients with primary or secondary myelofibrosis (MF). However …
therapeutic modality for patients with primary or secondary myelofibrosis (MF). However …
Novel therapies vs hematopoietic cell transplantation in myelofibrosis: who, when, how?
J England, V Gupta - Hematology, 2021 - ashpublications.org
Myelofibrosis is one of the classical Philadelphia chromosome–negative myeloproliferative
neoplasms characterized by progressive marrow failure and chronic inflammation …
neoplasms characterized by progressive marrow failure and chronic inflammation …
Allogeneic hematopoietic cell transplantation versus drugs in myelofibrosis: the risk-benefit balancing act
A Tefferi - Bone Marrow Transplantation, 2010 - nature.com
Primary myelofibrosis (PMF) is a chronic myeloid malignancy characterized by stem cell-
derived clonal myeloproliferation, anemia, marked hepatosplenomegaly and other …
derived clonal myeloproliferation, anemia, marked hepatosplenomegaly and other …
Current challenges in stem cell transplantation in myelofibrosis
N Kröger - Current hematologic malignancy reports, 2015 - Springer
Primary or post-ET/PV myelofibrosis is one of the Philadelphia-negative myeloproliferative
neoplasms with worst survival. Allogeneic stem cell transplantation (ASCT) can cure a …
neoplasms with worst survival. Allogeneic stem cell transplantation (ASCT) can cure a …
Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis
J Perram, DM Ross, D McLornan… - American Journal of …, 2022 - Wiley Online Library
Myelofibrosis (MF) is a clonal myeloproliferative neoplasm characterized by inflammation,
marrow fibrosis, and an inherent risk of blastic transformation. Hematopoietic allogeneic …
marrow fibrosis, and an inherent risk of blastic transformation. Hematopoietic allogeneic …